Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;23(1):44-58.
doi: 10.1089/ten.TEB.2016.0181. Epub 2016 Sep 30.

A Clinical, Biological, and Biomaterials Perspective into Tendon Injuries and Regeneration

Grace Walden  1 , Xin Liao  1 , Simon Donell  2   3 , Mike J Raxworthy  4   5 , Graham P Riley  6 , Aram Saeed  1
Affiliations

A Clinical, Biological, and Biomaterials Perspective into Tendon Injuries and Regeneration

Grace Walden et al. Tissue Eng Part B Rev. 2017 Feb.

Abstract

Tendon injury is common and debilitating, and it is associated with long-term pain and ineffective healing. It is estimated to afflict 25% of the adult population and is often a career-ending disease in athletes and racehorses. Tendon injury is associated with high morbidity, pain, and long-term suffering for the patient. Due to the low cellularity and vascularity of tendon tissue, once damage has occurred, the repair process is slow and inefficient, resulting in mechanically, structurally, and functionally inferior tissue. Current treatment options focus on pain management, often being palliative and temporary and ending in reduced function. Most treatments available do not address the underlying cause of the disease and, as such, are often ineffective with variable results. The need for an advanced therapeutic that addresses the underlying pathology is evident. Tissue engineering and regenerative medicine is an emerging field that is aimed at stimulating the body's own repair system to produce de novo tissue through the use of factors such as cells, proteins, and genes that are delivered by a biomaterial scaffold. Successful tissue engineering strategies for tendon regeneration should be built on a foundation of understanding of the molecular and cellular composition of healthy compared with damaged tendon, and the inherent differences seen in the tissue after disease. This article presents a comprehensive clinical, biological, and biomaterials insight into tendon tissue engineering and regeneration toward more advanced therapeutics.

Keywords: implant; injectable scaffold; tendinopathy; tendon injury; tendon rupture; tissue engineering.

PubMed Disclaimer

Conflict of interest statement

No competing financial interests exist.

Figures

<b>FIG. 1.</b>
FIG. 1.
Showing tendon structures (physiological, tendinopathy, and tendon rupture) and stress–strain curve for tendon tissue. (a) Illustrating the tendon sub-structures (including fascicles, fibers, fibril, and tropocollagen), with relative dimensions thereof in a healthy tendon (top-left), and scar tissue formation in tendinopathy (middle-left)—characterized by disorganized collagen fibers, scar tissue formation, and tendon rupture (bottom-left) in which the two ends become separated and frayed. (b) A stress–strain curve for tendon tissue. At strains up to 2%, the tendon retains a characteristic crimped structure; this is known as the toe region. Under mild mechanical loads and stresses below 4%, the tissue is able to lengthen its crimped collagen fibers and withstand forces. This is known as the linear region, and it is representative of the physiological range of the tendon tissue. Strains above 4% can result in small micro-tears within the tissue, and tendinopathy can develop. Repeated micro-tears and strains above 8% can result in the tissue rupturing. The blue dotted line depicts the toe, linear and failure regions on the stress/strain curve.
<b>FIG. 2.</b>
FIG. 2.
Tissue engineering strategies for tendon regeneration, including (a) injectable therapeutics containing cells, proteins, or genes, which can be directly injected to the site of the injury. (b) Regenerative implants containing a combination of cells, protein, and scaffold materials, which can be directly implanted and sutured in tendon rupture injuries.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rickert M., Wang H., Wieloch P., Lorenz H., Steck E., Sabo D., and Richter W. Adenovirus-mediated gene transfer of growth and differentiation factor-5 into tenocytes and the healing rat Achilles tendon. Connect Tissue Res 46, 175, 2005 - PubMed
    1. Gaspar D., Spanoudes K., Holladay C., Pandit A., and Zeugolis D. Progress in cell-based therapies for tendon repair. Adv Drug Deliv Rev 84, 240, 2015 - PubMed
    1. Thorpe C.T., Spiesz E.M., Chaudhry S., Screen H.R.C., and Clegg P.D. Science in brief: recent advances into understanding tendon function and injury risk. Equine Vet J 47, 137, 2015 - PubMed
    1. Docheva D., Muller S.A., Majewski M., and Evans C.H. Biologics for tendon repair. Adv Drug Deliv Rev 84, 222, 2015 - PMC - PubMed
    1. Lomas A.J., Ryan C.N., Sorushanova A., Shologu N., Sideri A.I., Tsioli V., Fthenakis G.C., Tzora A., Skoufos I., Quinlan L.R., O'Laighin G., Mullen A.M., Kelly J.L., Kearns S., Biggs M., Pandit A., and Zeugolis D.I. The past, present and future in scaffold-based tendon treatments. Adv Drug Deliv Rev 84, 257, 2015 - PubMed

Substances

LinkOut - more resources